Drug Profile

Testosterone enanthate auto-injection - Antares Pharma

Alternative Names: QuickShot testosterone; Testosterone enantate - Antares Pharma; TRT - Antares Pharma; Vibex QS T; Vibex QuickShot T; XYOSTED

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antares Pharma
Developer Antares Pharma; Halozyme Therapeutics
Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
Mechanism of Action Androgen receptor agonists; Testosterone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Feb 2025 Phase-III clinical trials in Hypogonadism (In adolescents) in USA (SC) (NCT06689085)
14 Nov 2024 Halozyme Therapeutics plans a phase III trial for Hypogonadism (In adolescents) (SC, injection) in January 2025 (NCT06689085)
24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com